Results 11 to 20 of about 247,670 (219)

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

New England Journal of Medicine, 2022
BACKGROUND The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells.
M. Dickinson, C. Carlo-Stella, F. Morschhauser, E. Bachy, P. Corradini, G. Iacoboni, C. Khan, T. Wróbel, F. Offner, M. Trněný, Shang-Ju Wu, G. Cartron, M. Hertzberg, A. Sureda, D. Pérez-Callejo, L. Lundberg, J. Relf, M. Dixon, E. Clark, K. Humphrey, M. Hutchings   +20 more
semanticscholar   +1 more source

Diffuse large B-cell lymphoma

Pathology, 2018
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30-40% of all cases in different geographic regions. Patients most often present with a rapidly growing tumour mass in single or multiple, nodal or extranodal sites.
Shaoying, Li, Ken H, Young, L Jeffrey, Medeiros   +2 more
  +6 more sources

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Nature Medicine, 2022
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL).
E. Bachy, S. le Gouill, Roberta Di Blasi, P. Sesques, G. Manson, G. Cartron, D. Beauvais, L. Roulin, F. Gros, M. Rubio, P. Bories, J. Bay, C. C. Llorente, S. Choquet, R. Casasnovas, M. Mohty, S. Guidez, M. Joris, M. Loschi, S. Carras, J. Abraham, A. Chauchet, Laurianne Drieu La Rochelle, B. Deau-Fischer, O. Hermine, T. Gastinne, J. Tudesq, E. Gat, F. Broussais, C. Thieblemont, R. Houot, F. Morschhauser   +31 more
semanticscholar   +1 more source

Intravascular diffuse large B-cell lymphoma with acquired ichthyosis: A case report

SAGE Open Medical Case Reports, 2023
Intravascular diffuse large B-cell lymphoma is an exceedingly rare subtype of B-cell lymphomas. This cancer is often associated with poor prognosis and can be lethal if left untreated.
Zainab Ridha, Hanieh Zargham, May Chergui, Elena Netchiporouk   +3 more
doaj   +1 more source

Epidemiology and etiology of diffuse large B-cell lymphoma.

Seminars in hematology (Print), 2023
As the most common non-Hodgkin lymphoma subtype, diffuse large B-cell lymphoma (DLBCL) incidence patterns generally parallel that for NHL overall. Globally, DLBCL accounts for a third of all NHLs, ranging between 20% and 50% by country.
Sophia S. Wang
semanticscholar   +1 more source

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India

South Asian Journal of Cancer, 2019
Background: Gastrointestinal tract (GIT) is the most common extranodal site for non-Hodgkin's lymphoma (NHL) and constitutes about 10%-15% of all NHL. This was a prospective study to evaluate the epidemiological, clinicopathological characteristics, and ...
Babu Suresh, Vikas Asati, K C Lakshmaiah, Govind Babu, D Lokanatha, Linu Abraham Jacob, K N Lokesh, A H Rudresh, L K Rajeev, Saldanha Smitha, Abhishek Anand, Rajesh Patidar, C S Premalata   +12 more
doaj   +1 more source

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

New England Journal of Medicine, 2019
BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has relapsed after stem‐cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel
S. Schuster, M. Bishop, C. Tam, E. Waller, P. Borchmann, J. Mcguirk, U. Jäger, S. Jaglowski, C. Andreadis, J. Westin, I. Fleury, V. Bachanova, R. Foley, J. Ho, S. Mielke, J. Magenau, H. Holte, Serafino Pantano, L. Pacaud, R. Awasthi, J. Chu, Ö. Anak, G. Salles, R. Maziarz   +23 more
semanticscholar   +1 more source

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.

Cancer Cell, 2020
The development of precision medicine approaches for diffuse large B cell lymphoma (DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity. Recent multiplatform genomic studies revealed the existence of genetic subtypes of
George W. Wright, D. Huang, J. Phelan, Zana Coulibaly, S. Roulland, R. Young, James Q Wang, R. Schmitz, Ryan D. Morin, Jeffrey Tang, A. Jiang, Aleksander Bagaev, O. Plotnikova, N. Kotlov, Calvin A. Johnson, W. Wilson, D. Scott, L. Staudt   +17 more
semanticscholar   +1 more source

Primary mediastinal lymphoma: diagnosis and treatment options. [PDF]

, 2014
Primary mediastinal large B-cell lymphoma (PMBCL) is a unique B-cell lymphoma variant that arises from a putative thymic medulla B cell. It constitutes 2-4% of non-Hodgkin lymphomas and occurs most frequently in young females. PMBCL is characterized by a
DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio, Perrone, Salvatore, Russo, E   +4 more
core   +1 more source